2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Burkitt Lymphoma
5
Leukemia
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Recurrence
2
Leukemia, Myelomonocytic, Juvenile
2
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Down Syndrome
1
Dendritic Cell Sarcoma, Interdigitating
1
Cardiotoxicity
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Cyclophosphamide
447
Rituximab
406
Etoposide
225
Vincristine
217
Doxorubicin
204
Filgrastim
201
Prednisone
178
Cytarabine
160
Radiotherapy
152
fludarabine phosphate
148
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
130
Melphalan
128
fludarabine
116
Busulfan
101
Dexamethasone
93
Tacrolimus
76
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
72
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
63
Bendamustine Hydrochloride
63
Lenalidomide
62
Cyclosporine
62
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
hydrocortisone hemisuccinate
×
Clear all
NCT01230983
2013-06-06
T-Cell #4
Children's Oncology Group
Phase 3
Completed
573 enrolled